Physician profile
Barbara T Keyes
NPI 1427044148
$7,333.45
in general payments reported to CMS, 2019-2025
23 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $795 · 2021: $1,049 · 2022: $1,235 · 2023: $1,269 · 2024: $1,130 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167 · Education: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.02 |
| Education | $558.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,676.22 | 2019-2025 | |
| Janssen Biotech, INC. | $1,521.66 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $789.12 | 2020-2025 | Ilumya |
| Ucb, INC. | $651.52 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $565.91 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $485.95 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $406.44 | 2019-2025 | |
| Pfizer INC. | $362.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $193.48 | 2022-2024 | Sotyktu |
| Amgen INC. | $169.16 | 2019-2025 | Otezla |
| Galderma Laboratories, L.P. | $95.60 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $93.69 | 2022-2024 | Vtama |
| Genzyme Corporation | $93.22 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Sandoz INC. | $43.26 | 2019-2024 | Hyrimoz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $20.51 | 2020 | |
| Incyte Corporation | $18.59 | 2025 | Opzelura |
| Epi Health, LLC | $17.26 | 2022 | |
| Almirall LLC | $14.21 | 2019 | |
| Journey Medical Corporation | $13.46 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $12.78 | 2025 | |
| Organon LLC | $3.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Keyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.